Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Pfizer Begins Selling Viagra Online to Battle Fake Drugs

Don't Miss Out —
Follow us on:

May 7 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, has started offering its impotence drug Viagra through a company-sponsored website to combat counterfeit versions that are sold online.

Men prescribed the erectile dysfunction medicine can order the drug at Viagra.com. The prescriptions will be verified and completed by Woonsocket, Rhode Island-based CVS Caremark Corp., the largest U.S. provider of prescription drugs.

“There are almost 24 million searches a year for Viagra online,” said Victor Clavelli, senior director in Pfizer’s primary care unit, said in a company statement. By helping men obtain Viagra through the official website, the company seeks to “rein in the distribution” of fake versions of the drug.

Pfizer in 2011 conducted a chemical analysis of pills purchased from 22 websites that ranked high in an online search for the phrase “buy Viagra.” The analysis found that roughly 80 percent of the pills claimed to be Viagra were counterfeit and didn’t contain full doses of the active ingredient as advertised, the New York-based company said in the statement.

Sales of Viagra were $2.05 billion in 2012, Pfizer reported in a regulatory filing.

The website “is providing a resource for patients to be able to get their prescription in a safe and legitimate way,” Jennifer Kokell, a spokeswoman for Pfizer, said in a telephone interview. “We expect to learn from this.”

Pfizer shares rose 1.1 percent to $29.03 at the close in New York. The company has gained 29 percent in the past 12 months.

To contact the reporter on this story: Robert Langreth in New York at rlangreth@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net